Search Result

Results for "

AKT-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (37) Ack1 (1) ADC Cytotoxin (1) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (13) Autophagy (2) Bacterial (2) c-Fms (1) c-Met/HGFR (1) CDK (1) ClpP (2) COX (2) EGFR (2) Endogenous Metabolite (2) ERK (1) GABA Receptor (1) GLUT (1) HDAC (1) HIV (2) IGF-1R (1) Interleukin Related (2) Isotope-Labeled Compounds (1) JNK (4) Keap1-Nrf2 (1) MALT1 (1) Mitochondrial Metabolism (1) NF-κB (1) Organoid (2) p38 MAPK (2) Parasite (2) PI3K (4) PKA (3) PKC (2) PPAR (2) Prolyl Endopeptidase (PREP) (3) Reactive Oxygen Species (2) Ribosomal S6 Kinase (RSK) (3) ROCK (3) ROR (1) STAT (1) VEGFR (1)
By Research Areas:	Cancer (42) Cardiovascular Disease (3) Endocrinology (1) Infection (4) Inflammation/Immunology (6) Metabolic Disease (6) Neurological Disease (5)

By Targets:

Akt (37)

Ack1 (1)

ADC Cytotoxin (1)

AMPK (1)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (13)

Autophagy (2)

Bacterial (2)

c-Fms (1)

c-Met/HGFR (1)

CDK (1)

ClpP (2)

COX (2)

EGFR (2)

Endogenous Metabolite (2)

ERK (1)

GABA Receptor (1)

GLUT (1)

HDAC (1)

HIV (2)

IGF-1R (1)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

JNK (4)

Keap1-Nrf2 (1)

MALT1 (1)

Mitochondrial Metabolism (1)

NF-κB (1)

Organoid (2)

p38 MAPK (2)

Parasite (2)

PI3K (4)

PKA (3)

PKC (2)

PPAR (2)

Prolyl Endopeptidase (PREP) (3)

Reactive Oxygen Species (2)

Ribosomal S6 Kinase (RSK) (3)

ROCK (3)

ROR (1)

STAT (1)

VEGFR (1)

By Research Areas:

Cancer (42)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (6)

Metabolic Disease (6)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Akt Dan family AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18296

*AKT-IN-1* 5 Publications Verification	Akt	Cancer
AKT-IN-1 is an allosteric AKT inhibitor with an IC₅₀ of 1.042 μM.

HY-144806

PI3K/AKT-IN-1 5+ Cited Publications	PI3K Akt Apoptosis	Cancer
PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC₅₀ of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis ^[1].

HY-145244

APN/AKT-IN-1	Akt	Cancer
APN/AKT-IN-1 is a potent and dual inhibitor of APN and AKT with IC₅₀s of 0.21 and 0.27 μM, respectively. APN/AKT-IN-1 can effectively inhibit the phosphorylation of GSK3β, the intracellular substrate of AKT ^[1].

HY-161891

EGFR/Akt-IN-1	EGFR Akt	Cancer
EGFR/Akt-IN-1 (compound 17) is a potent inhibitor of EGFR/Akt, with the IC₅₀s of 12.89 μM and 10.88 μM in A549 cells, respectively. EGFR/Akt-IN-1 arrestes the cell cycle at the S phase ^[1].

HY-161861

VEGFR-2/AKT-IN-1	VEGFR Akt	Cancer
VEGFR-2/AKT-IN-1 (compound 17) is a dual inhibitor of VEGFR-2 and AKT, with the IC₅₀*s of 0.164 μM and 0.452 μM, respectively. VEGFR-2/AKT-IN-1* has antitumor activity ^[1].**

HY-173007

ALK/PI3K/AKT-IN-1	Akt PI3K Anaplastic lymphoma kinase (ALK) CDK Apoptosis Mitochondrial Metabolism	Cancer
ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC₅₀ of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids ^[1].

HY-161351

STAT3/AKT-IN-1	Akt STAT Apoptosis	Cancer
STAT3/AKT-IN-1 is a dual inhibitor for the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signalling pathway, exhibits antitumor activity against gastric cancer and induces cell apoptosis in SGC-7901 cells ^[1].

HY-P10049

TAT-TCL1-Akt-in	Akt	Cancer
TAT-TCL1-Akt-in is an *Akt* inhibitor .

HY-16032

Akt1-IN-2	Akt	Cancer
AKT-I-1 is a selective inhibitor of *Akt1, with an IC₅₀* of 4.6 µM ^[1].

HY-162285

Anticancer agent 189	Akt	Cancer
Anticancer agent 189 (compound 4) is an anticancer agent that antagonizes CRC effects by targeting *AKT1* .

HY-112148

AKT-IN-2	Akt	Cancer
AKT-IN-2 is a potent, selective and orally bioavailable AKT inhibitor with an IC₅₀ of 5 nM for *AKT1* .

HY-122913

Borussertib	Akt	Cancer
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC₅₀ of 0.8 nM and a K_i of 2.2 nM for Akt ^wt .

HY-W750451

Reptoside	Akt	Cancer
Reptoside, an iridoid glucoside, is a DNA damaging active agent. Reptoside has strong interactions with Trp352 and Tyr335 in *AKT1* .

HY-15431

Capivasertib Maximum Cited Publications 61 Publications Verification AZD5363	Akt Autophagy	Cancer
Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC₅₀ of 3, 7 and 7 nM for *Akt1,Akt2* and Akt3, respectively.

HY-15965

Uprosertib 15+ Cited Publications GSK2141795	Akt	Cancer
Uprosertib (GSK2141795) is a potent and selective pan-Akt inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-147789

FPDT	Akt	Neurological Disease Cancer
FPDT is an anti-glioblastoma agent. FPDT displays the IC₅₀ value of 45–68 μM for GBM cells and >100 μM for astrocytes. Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway .

HY-15965A

Uprosertib hydrochloride GSK2141795 hydrochloride	Akt	Cancer
Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective pan-Akt inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-100018

BAY1125976 1 Publications Verification	Akt	Cancer
BAY1125976 is a selective allosteric *Akt1/Akt2* inhibitor; inhibits Akt1 and Akt2 activity with IC₅₀ values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

HY-13685

Miltefosine 10+ Cited Publications HePC; Hexadecyl phosphocholINe	Akt HIV Parasite	Infection Cancer
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the *PI3K/Akt* activity . Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT) .

HY-15727

Afuresertib 10+ Cited Publications GSK2110183; LAE002	Akt PKC ROCK	Cancer
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively ^[1] .

HY-15727A

Afuresertib hydrochloride 10+ Cited Publications GSK2110183 hydrochloride; LAE002 hydrochloride	Akt PKC ROCK	Cancer
Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively ^[1] .

HY-131055

Mytoxin B	ADC Cytotoxin PI3K Apoptosis	Cancer
Mytoxin B is an ADC cytotoxin. Mytoxin B is a satratoxin-type trichothecene macrolide and is similar to the effect of LY294002 (HY-10108). Mytoxin B induces cell apoptosis via PI3K/Akt pathway .

HY-122959

Kihadanin B	Akt PPAR	Metabolic Disease
Kihadanin B is a citrus limonoid that can be purified from the peels of immature Citrus unshiu. Kihadanin B suppresses adipogenesis through repression of the Akt-FOXO1-PPARγ axis in 3T3-L1 adipocytes ^[1].

HY-149989

Ack1 inhibitor 1	Ack1 Akt	Cancer
Ack1 inhibitor 1 is a potent, selective, and orally active inhibitor of *ACK1* kinase with an IC₅₀ value of 2.1 nM. Ack1 inhibitor 1 inhibits the phosphorylation of *ACK1* and activation of downstream *AKT*. Ack1 inhibitor 1 has anti-tumor activity ^[1].

HY-P99274

Xentuzumab 1 Publications Verification BI 836845; Anti-Human IGF1 and IGF2 RecombINant Antibody	IGF-1R	Cancer
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands *IGF1* and IGF2. Xentuzumab inhibits both of *IGF1* and IGF2 growth-promoting signalling and suppresses *AKT* activation .

HY-N0479

Licarin B 1 Publications Verification (-)-LicarIN B	PPAR GLUT	Metabolic Disease
Licarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans, improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway .

HY-161144

AKT-IN-21	Akt Apoptosis	Cancer
AKT-IN-21 (compound C36) is a potent AKT inhibitor with broad-spectrum cytotoxicity and anticancer activity. AKT-IN-21 also blocks the cell cycle and induces apoptosis of cancer cells by down-regulating the PI3K/AKT pathway .

HY-N9968

Cucurbitacin C	Akt Apoptosis	Cancer
Cucurbitacin C is a triterpenoid calabinoid that can be isolated from Cucurbitaceae plants. Cucurbitacin C has anti-cancer activity in vivo and in vitro. Cucurbitacin C can induce cell cycle arrest in G1 or G2/M phase and apoptosis by inhibiting *Akt* signaling .

HY-107597

Halicin 1 Publications Verification SU3327	JNK	Metabolic Disease Inflammation/Immunology
Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC₅₀ of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. Halicin shows less active against p38α and Akt kinase .

HY-P4790

Acetyl-Exenatide	PI3K Akt	Metabolic Disease
Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation ^[1].

HY-16071

AT13148 2 Publications Verification	Akt PKA ROCK Ribosomal S6 Kinase (RSK)	Cancer
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC₅₀s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

HY-13685S1

Miltefosine-d4 HePC-d₄; Hexadecyl phosphocholINe-d₄	Isotope-Labeled Compounds Akt Parasite HIV	Infection Cancer
Miltefosine-d₄ (HePC-d₄) is deuterium labeled Miltefosine. Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the *PI3K/Akt* activity . Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT) .

HY-12059A

AT7867 dihydrochloride 5+ Cited Publications	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-158050

PXB17	c-Fms	Cancer
PXB17 can inhibit *CSF1R* (IC₅₀ = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC ^[1].

HY-12059

AT7867 5+ Cited Publications	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-121012

(rac)-AG-205	NF-κB Akt	Endocrinology
(rac)-AG-205 is a potent inhibitor of progesterone receptor membrane component 1 (Pgrmc1) that induces genes involved in sterol synthesis, including the INSIG1 protein, which forms a complex with PGRMC1. (rac)-AG-205 prevents neuronal resistance to hypoxic ischaemia by blocking NF-kB signalling and activation of the BDNF/PI3K/AKT pathway .

HY-155542

RORγ antagonist 1	ROR	Cancer
RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (K_D=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and *AKT/mTORC1* pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells ^[1].

HY-13425

Deguelin 5+ Cited Publications (-)-DeguelIN; (-)-cis-DeguelIN	Akt Autophagy Apoptosis	Cancer
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-107758

Y-29794 oxalate	Prolyl Endopeptidase (PREP)	Cancer
Y-29794 oxalate is a selective, orally active and blood-brain barrier permeable non-peptide prolyl endopeptidase inhibitor. Y-29794 oxalate blocks the *IRS1-AKT-mTORC1* pathway and inhibits tumor growth. Y-29794 oxalate is also effective in inhibiting the progression of Aβ-like deposition in the hippocampus of aging-accelerated mice (SAM) ^[1] .

HY-15186

Ipatasertib 40+ Cited Publications GDC-0068; RG7440	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for *Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt* leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models ^[1] .

HY-15186C

Ipatasertib tosylate GDC-0068 tosylate; RG7440 tosylate	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for *Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt* leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models ^[1] .

HY-N2292

Kinsenoside 3 Publications Verification	Keap1-Nrf2 Apoptosis	Inflammation/Immunology
Kinsenoside is the main active ingredient of the genus plant, and has various biological activities. Kinsenoside and Nrf2 depend on the protection of nuclear cells (NPCs), which significantly reduces their ability to survive. Kinsenoside Active NPC Medium AKT-ERK1/2-Nrf2 Signal passage, Prevent physical decline, aging, harmonious physical function impairment. Kinsenoside can improve the puncture guide model for intermediate vertebral wall discharge (IDD).

HY-163006

EGFR/c-Met-IN-1	EGFR c-Met/HGFR	Cancer
EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of EGFR/c-Met. The IC₅₀ for inhibiting EGFR ^L858R and c-Met is 68.1 nM and 0.26 nM respectively. . EGFR/c-Met-IN-1 induces apoptosis and cell cycle arrest in A549-P cells, downregulating the phosphorylation of EGFR, c-Met, and downstream AKT. EGFR/c-Met-IN-1 inhibits tumor growth in vitro and in vivo ^[1].

HY-15113

Y-29794	Prolyl Endopeptidase (PREP)	Neurological Disease Cancer
Y-29794 is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC₅₀ of 3 nM and a K_i of 0.95 nM. Y-29794 enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 exhibits anticancer activity through inhibition of the *IRS1-AKT-mTORC1* pathway. Y-29794 penetrates the brain-blood barrier (BBB) ^[1] .

HY-15113A

Y-29794 tosylate	Prolyl Endopeptidase (PREP)	Neurological Disease Cancer
Y-29794 tosylate is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC₅₀ of 3 nM and a K_i of 0.95 nM. Y-29794 tosylate enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 tosylate exhibits anticancer activity through inhibition of the *IRS1-AKT-mTORC1* pathway. Y-29794 tosylate penetrates the brain-blood barrier (BBB) ^[1] .

HY-N7676

Marein 2 Publications Verification	AMPK HDAC	Cardiovascular Disease Neurological Disease Metabolic Disease
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects ^[1] .

HY-162268

MALT1-IN-13	MALT1 Apoptosis	Inflammation/Immunology Cancer
MALT1-IN-13 (compound 10m) is inhibitor for mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which to binds MALT1 protease covalently and irreversibly, inhibits MALT1 with the IC₅₀ of 1.7 μM. MALT1-IN-13 inhibits proliferation against ABC-DLBCL and induces apoptosis in ABC-DLBCL HBL1. MALT1-IN-13 regulates mTOR and PI3K-Akt pathways .

HY-N1181

Tamarixetin 1 Publications Verification 4'-O-Methyl QuercetIN	Endogenous Metabolite ClpP Bacterial Apoptosis Akt Interleukin Related COX JNK p38 MAPK Reactive Oxygen Species	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Tamarixetin (4'-O-Methyl Quercetin) is an orally active natural flavonoid derivative of quercetin and caseinolytic protease p (ClpP) inhibitor with anti-inflammatory, antioxidant and antitumor effects. Tamarixetin inhibits the hydrolytic activity of ClpP to the fluorescent substrate Suc-LY-AMC with an IC₅₀ of 49.73 μM, which can be used for the study of Staphylococcus aureus infection. Tamarixetin inhibits tumor cell growth, induces apoptosis, and cell cycle arrest. Tamarixetin prevents cardiac hypertrophy by inhibiting the NFAT and *AKT* pathways .

HY-N1181R

Tamarixetin (Standard)	Endogenous Metabolite ClpP Bacterial Apoptosis Akt Interleukin Related COX JNK p38 MAPK Reactive Oxygen Species	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Tamarixetin (Standard) is the analytical standard of Tamarixetin. This product is intended for research and analytical applications. Tamarixetin (4'-O-Methyl Quercetin) is an orally active natural flavonoid derivative of quercetin and caseinolytic protease p (ClpP) inhibitor with anti-inflammatory, antioxidant and antitumor effects. Tamarixetin inhibits the hydrolytic activity of ClpP to the fluorescent substrate Suc-LY-AMC with an IC₅₀ of 49.73 μM, which can be used for the study of Staphylococcus aureus infection. Tamarixetin inhibits tumor cell growth, induces apoptosis, and cell cycle arrest. Tamarixetin prevents cardiac hypertrophy by inhibiting the NFAT and *AKT* pathways .

HY-N7110

6-Hydroxyflavone	Akt ERK JNK GABA Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
6-Hydroxyflavone is an orally effective flavonoid compound. 6-Hydroxyflavone can inhibit LPS (HY-D1056) -induced NO production and has anti-inflammatory effects. 6-Hydroxyflavone promotes osteoblast differentiation by activating *AKT, ERK 1/2* and JNK signaling pathways. 6-Hydroxyflavone has an inhibitory effect on bovine hemoglobin (BHb) glycosylation. 6-Hydroxyflavone has a kidney protective effect. In addition, 6-Hydroxyflavone enhances GABA-induced current through the Benzodiazepine sites of γ-aminobutyric acid (GABA_A) receptors. 6-Hydroxyflavone shows a clear preference for α2 - and α3 - subtypes, which play an anti-anxiety role ^[1] .

Cat. No.	Product Name	Target	Research Area